Immediate Impact
64 standout
Citing Papers
Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
2024 Standout
Works of David Nathanson being referenced
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
2017
Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David Nathanson | 591 | 100 | 297 | 174 | 21 | 794 | |
| Renato O. Crajoinas | 453 | 88 | 264 | 176 | 24 | 695 | |
| Yuri Nishino | 427 | 50 | 194 | 128 | 25 | 874 | |
| Richard W Simpson | 673 | 63 | 341 | 226 | 18 | 949 | |
| Cendrine Cabou | 365 | 91 | 336 | 296 | 27 | 959 | |
| Motofumi Sasaki | 325 | 49 | 200 | 174 | 16 | 759 | |
| Markus Alter | 452 | 133 | 217 | 153 | 23 | 843 | |
| Masanori Fukazawa | 491 | 43 | 370 | 293 | 33 | 832 | |
| Gilles‐Jacques Rivière | 245 | 100 | 347 | 97 | 19 | 849 | |
| Joanne Hsieh | 483 | 45 | 316 | 308 | 16 | 969 | |
| Atsuko Abiko | 331 | 60 | 284 | 198 | 26 | 780 |
All Works
Loading papers...